Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
First-in-human just means it’s the first time that specific therapy is being tested on humans instead of animals (e.g. mice, dogs, monkeys), and the primary objective of the trial is to test that it’s safe for use in humans. It doesn’t refer to the concept of gene editing or lowering cholesterol.
First-in-human just means it’s the first time that specific therapy is being tested on humans instead of animals (e.g. mice, dogs, monkeys), and the primary objective of the trial is to test that it’s safe for use in humans. It doesn’t refer to the concept of gene editing or lowering cholesterol.